Exelixis: Zanzalintinib as a Great Hope in Cancer Therapies Before FDA Approval
Reading Time: 3 minutes
Business Model: Exelixis focuses on targeted cancer therapies with kinase inhibitors. The main product Cabometyx is distributed both directly and through partners, primarily treating kidney, liver, and thyroid cancers. Clinical Progress: Recent data from the Phase 3 study CABINET demonstrate a reduction in disease progression risk of up to 74% in neuroendocrine tumors. Strong Quarterly Results: In the first quarter of 2026, the company surpassed analyst expectations with a revenue of $610.8 million and earnings per share of $0.87, providing...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
